66 related articles for article (PubMed ID: 27128459)
1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate, a novel inhaled corticosteroid, in children aged 5-11 years with persistent asthma: A randomized trial.
Oliver A; Allen A; VanBuren S; Hamilton M; Tombs L; Kempsford R; Qaqundah P
Clin Pharmacol Drug Dev; 2014 Mar; 3(2):144-50. PubMed ID: 27128459
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
6. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
[TBL] [Abstract][Full Text] [Related]
7. Knemometry Assessment of Short-term Growth in Children With Asthma Receiving Fluticasone Furoate for 2 Weeks: A Randomized, Placebo-controlled, Crossover Trial.
Wolthers OD; Stone S; Bareille P; Tomkins S; Khindri S
Clin Ther; 2017 Jun; 39(6):1191-1199. PubMed ID: 28545804
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Kempsford R; Qaqundah P
Clin Pharmacol Drug Dev; 2014 May; 3(3):215-221. PubMed ID: 26097789
[TBL] [Abstract][Full Text] [Related]
9. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
Nakahara N; Wakamatsu A; Kempsford R; Allen A; Yamada M; Nohda S; Hirama T
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic-pituitary-adrenocortical axis of children with asthma.
Bareille P; Tomkins S; Imber V; Tayob M; Dunn K; Mehta R; Khindri S
Allergy Asthma Clin Immunol; 2020; 16():11. PubMed ID: 32042286
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
Busse WW; Bleecker ER; Bateman ED; Lötvall J; Forth R; Davis AM; Jacques L; Haumann B; Woodcock A
Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
[TBL] [Abstract][Full Text] [Related]
12. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
Bleecker ER; Bateman ED; Busse WW; Woodcock A; Frith L; House KW; Jacques L; Davis AM; Haumann B; Lötvall J
Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
Kempsford RD; Oliver A; Bal J; Tombs L; Quinn D
Respir Med; 2013 Dec; 107(12):1873-80. PubMed ID: 24200619
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects.
Allen A; Bal J; Cheesbrough A; Hamilton M; Kempsford R
Br J Clin Pharmacol; 2014 May; 77(5):808-20. PubMed ID: 24152086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
18. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
19. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
Bernstein DI; Bateman ED; Woodcock A; Toler WT; Forth R; Jacques L; Nunn C; O'Byrne PM
J Asthma; 2015; 52(10):1073-83. PubMed ID: 26291137
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.
LaForce CF; Pearlman DS; Ruff ME; Silvers WS; Weinstein SW; Clements DS; Brown A; Duke S; Harding SM; House KW
Ann Allergy Asthma Immunol; 2000 Nov; 85(5):407-15. PubMed ID: 11101186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
